Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/16/2863493/0/en/Eloxx-Pharmaceuticals-Provides-ELX-02-and-ZKN-013-Program-Updates.html
https://www.globenewswire.com//news-release/2024/03/13/2845650/0/en/Almirall-and-Eloxx-Pharmaceuticals-Enter-into-Exclusive-Agreement-to-license-ZKN-013-for-rare-dermatological-diseases.html
https://www.globenewswire.com//news-release/2023/11/13/2779493/0/en/Eloxx-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2023/10/09/2756643/0/en/Eloxx-Pharmaceuticals-Reports-Additional-Confirmation-that-All-Nonsense-Mutation-Alport-Syndrome-Patients-Treated-with-ELX-02-in-Phase-2-Study-had-Improvement-in-Kidney-Morphology-.html
https://www.globenewswire.com//news-release/2023/09/19/2745534/0/en/Eloxx-Pharmaceuticals-Announces-2-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html
https://www.globenewswire.com//news-release/2023/09/18/2744637/0/en/Eloxx-Pharmaceuticals-Reports-Independent-Confirmation-of-Positive-Biopsy-Results-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html
https://www.globenewswire.com//news-release/2023/09/07/2739454/0/en/Eloxx-Pharmaceuticals-Provides-Program-Updates-on-ELX-02-and-ZKN-013.html
https://www.globenewswire.com/news-release/2023/08/14/2724500/0/en/Eloxx-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2023/08/14/2724338/0/en/Eloxx-Pharmaceuticals-Reports-Drug-Response-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html
https://www.globenewswire.com/news-release/2023/08/03/2718175/0/en/Eloxx-Pharmaceuticals-Granted-Extension-by-Nasdaq-to-Regain-Compliance-with-the-Market-Value-of-Listed-Securities-Continued-Listing-Requirement.html